Over the last four decades the survival of paediatric patients with acute myeloid leukaemia has gradually increased to 70% in high-income countries. The therapy is very intensive and associated with many acute and long-term side effects. The early death rate has been reduced to 1–4%. The acute toxicity is a limiting factor for improving survival in low-income countries. Transplant is associated with more endocrinological late effects while cardiotoxicity is more common after relapse. Reducing the physical costs of therapy without jeopardizing survival may be accomplished by optimal supportive care, less cardiotoxic anthracyclines, less consolidation courses and strict indications for stem cell transplantation. Analysing scenarios with different frequency of transplantation in first complete remission show similar overall survival rates, indicating that almost all patients can be spared the procedure in first remission. Reducing relapse risk is an effective way of reducing toxicity and more targeted therapy and improved risk group stratifications are needed.
CITATION STYLE
Hasle, H., & Kaspers, G. J. L. (2017, January 1). Strategies for reducing the treatment-related physical burden of childhood acute myeloid leukaemia – a review. British Journal of Haematology. Blackwell Publishing Ltd. https://doi.org/10.1111/bjh.14419
Mendeley helps you to discover research relevant for your work.